Ariadne Genomics said this week that it will provide bioinformatics resources for a European project that aims to identify non-invasive biomarkers for monitoring neuromuscular diseases, with a particular focus on Duchenne and Becker muscular dystrophies and collagen VI myopathies.
The three-year project, called BIO-NMD, has been awarded €5.5 million ($6.9 million) from the European Union and another €2 million ($2.5 million) from industrial partners.
Participating organizations in the project include Italy's Universities of Ferrara, Padova, Milan, and Rome; Leiden University Medical Center in the Netherlands; the University of Newcastle upon Tyne and University College London in the UK; France's National Health and Medical Research Institute; Sweden's Royal Institute of Technology, and Life Technologies' Applied Biosystems business.
Ariadne said that it will focus on providing bioinformatics tools that can identify functional pathways and potential targets, as well as tools for integrating data outflow.
The company plans to use Pathway Studio, its data mining and visualization software, to integrate data and information flow and will also build mechanistic models and pathways for neuromuscular diseases and interpret -omic data generated by the consortium.
The first update workshops for the consortium will be held this month in London. During the workshops, consortium members will present and describe possible outcomes for the project and identify links for future collaborations with industry.